Escala Medical Raises $4.5 Million for Global Expansion of Women’s Health Solutions

Escala Medical Secures $4.5 Million in Funding

Escala Medical Ltd., a pioneering name in femtech, recently announced the successful completion of a funding round, securing $4.5 million to further its global expansion efforts. This funding comes on the heels of a €2.5 million grant received from the EIC Accelerator program in October 2023, which underscores the company’s innovative approach to addressing women's health issues, particularly Pelvic Organ Prolapse (POP).

Aiming for Global Reach

The funds raised will primarily focus on boosting Escala's commercial operations in the United States. The company’s flagship product, the Mendit device, has already received FDA approval and was launched in the U.S. market in 2023. Since then, it has facilitated hundreds of successful procedures, demonstrating its effectiveness and potential to transform women's healthcare.

The investment will also enable Escala to prepare for its entry into the European market pending CE approval. Furthermore, a recent distribution agreement with a partner in Singapore will pave the way for expansion into Southeast Asia, highlighting Escala’s ambition for international growth.

Leadership Views on Funding

Dr. Edit Goldberg, the CEO of Escala, said, "This funding marks an important milestone as we continue to scale our operations and bring our breakthrough technology to more women worldwide. We pride ourselves on having the support of the EIB and our private investors, and remain committed to developing the next generation of our Mendit device to improve outcomes and access for millions of women suffering from organ prolapse."

In addition, Dr. Robert D. Auerbach, Chairman of Escala, expressed his gratitude for being selected for the EIC Accelerator program. He noted that receiving both a grant and equity investment from the EIC Fund represents a significant endorsement of Escala's technology, team, and vision.

Support from the EIC Fund

The EIC Fund, established by the European Commission, has a mandate to support companies that are innovating across various sectors and bridging market gaps. Svetoslava Georgieva, the Chair of the EIC Fund Board, remarked, "The EIC Fund is proud to support visionary companies like Escala. Their work exemplifies the transformative potential we aim to nurture through the EIC. This funding marks a significant milestone in their journey to bring much-needed innovation to women's health."

A Bright Future Ahead

Currently, Escala boasts a robust direct sales team in the U.S., and with the positive clinical outcomes of their products coupled with a surge in international demand, the company is well-positioned for substantial growth in 2025 and beyond.

As a part of The Trendlines Group Ltd. portfolio, Escala continues to commit itself to revolutionary solutions for pelvic organ prolapse treatment, shifting care from hospital settings to outpatient facilities. This innovative approach ensures that women at all stages of this health issue receive the care and solutions they need.

In conclusion, as Escala Medical gears up for its exciting journey of expansion, it is clear that the company's resolve to improve women’s health issues is holding strong, with significant backing from the EIC Fund and private investors. The landscape of women's health technology is on the brink of transformation, largely thanks to the visionary strategies of pioneering companies like Escala.